Clinical managements for severe covid-19 patients with pneumonia and acute respiratory distress: basic recommendation to reduce community mortality

Coronavirus Disease 2019 (COVID-19), caused by a novel corona virus (SARS-CoV-2), is a highly contagious disease. Most of the infected patients have mild symptoms including fever, fatigue and cough. But in severe cases, patients can progress rapidly and develop to the acute respiratory distress syndrome, septic shock, metabolic acidosis and coagulopathy. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative agent of corona virus disease 2019 (COVID-19), which was declared a global pandemic by the World Health Organization on 11th March 2020. The treatment guidelines for COVID-19 vary between countries, yet there is no approved treatment to date. To report any evidence of care and therapeutics used for the management of patients withCOVID-19 in clinical practice since emergence of the virus to reduce mortality. A systematic review protocol was developed based on the PRISMA statement. Articles for review were selected from Embase, Medline and Google Scholar. Readily accessible peer-reviewed, full articles in English published from 1st December 2019 to 26thMarch 2020 was included. The search terms included combinations of: COVID, SARS-COV-2, glucocorticoids, convalescent plasma, antiviral and antibacterial. There were no restrictions on the types of study eligible for inclusion.